Background: Taxanes are frequently used in the treatment of breast cancer. CHFR (checkpoint with forkhead and ringfinger domains) is a novel biomarker of resistance to microtubule targeting agents that can help individualize care and identify targets for overcoming this resistance. Our institution showed that high CHFR is associated with decreased response to taxanes and worse overall survival in patients with lung cancer. The current work evaluated the translational significance of CHFR in breast cancer. Methods: We studied a cohort of patients with triple negative breast cancer (TNBC), who were treated with pre-operative taxane-based chemotherapy followed by surgery. Archived paraffin-embedded tissue was stained for CHFR using immunohistochemistry. The level of protein expression was assessed by light microscopy and scored for intensity of staining and percentage of staining cells. CHFR expression was associated with pathologic complete response (pCR) and progression free survival (PFS). Covariates included age, race, stage, grade, tumor size, lymph node involvement, and type of chemotherapy. The univariate association with pCR was assessed using the chi-square test or Fisher’s exact test, where appropriate for categorical covariates; and ANOVA for numerical covariates. The univariate and multivariate association with PFS was assessed using the Cox proportional hazard model. Results: We analyzed tumor samples from 43 eligible patients, with median age of 57 years. 27.9% of patients achieved a pCR. 88.4% of patients had high CHFR expression. The expression of CHFR was not associated with clinical outcomes: pCR rate or PFS. All analyses were repeated on 30 patients treated with doxorubicin/cyclophosphamide and paclitaxel; the high expression of CHFR still did not have a statistically significant association with pCR or PFS though there was a marginal trend towards better PFS. Conclusions: In this cohort of TNBC patients, the majority of tumors had high CHFR expression. This did not associate with clinical outcomes: pCR and PFS. We hypothesize that TNBC may be characterized by high CHFR; evaluation of hormone receptor positive and HER2 positive tumors may be worth exploring.